Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Mink Intersects 7.1 Meters of 0.44% Ni, 0.28% Cu, 0.06% Co in Massive Sulphide at Warren Property (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Aeon Biopharma Inc AEON

Healthcare Biotechnology
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.


NYSEAM:AEON - Post by User

Aeon Biopharma Inc
<< Previous
 Bullboard Posts
User Avatar Image
(0)
•••
  • PressReleaseX
Post by PressReleaseon Mar 27, 2025 4:05pm
5 Views
Post# 36512459

New Press Release - AEON Biopharma Announces CEO Transition

New Press Release - AEON Biopharma Announces CEO Transition
– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors –– Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON)...read article.
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities